Jennifer A Marks1, Molly Wilgucki1, Stephen V Liu1, Joshua E Reuss2. 1. Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW LCCC, Podium B, Washington, DC, 20007, USA. 2. Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW LCCC, Podium B, Washington, DC, 20007, USA. Joshua.e.reuss@gunet.georgetown.edu.
Abstract
PURPOSE OF REVIEW: Antibody-drug conjugates (ADCs) are a class of therapeutics that combine target-specific monoclonal antibodies with cytotoxic chemotherapy. Here, we describe the components of ADCs and review their promising activity, safety, and applicability in non-small cell lung cancer (NSCLC). RECENT FINDINGS: Technological advancements have reinvigorated ADCs as a viable treatment strategy in advanced solid tumors. Several target-specific ADCs have shown promise in treatment-refractory NSCLC, including agents targeting HER2, HER3, TROP2, CEACAM5, and MET, among others, with multiple confirmatory phase 3 trials ongoing. Critically, ADCs have demonstrated efficacy signals in both driver mutation-positive and mutation-negative advanced NSCLC, reinforcing their potential as an efficacious treatment strategy that transcends diverse tumor biology in advanced NSCLC. ADCs are a promising class of anti-cancer therapeutics that have significant potential in advanced NSCLC. Beyond confirmatory phase 3 trials, several questions remain including optimal agent sequencing, combinatorial methods, and unique toxicity management.
PURPOSE OF REVIEW: Antibody-drug conjugates (ADCs) are a class of therapeutics that combine target-specific monoclonal antibodies with cytotoxic chemotherapy. Here, we describe the components of ADCs and review their promising activity, safety, and applicability in non-small cell lung cancer (NSCLC). RECENT FINDINGS: Technological advancements have reinvigorated ADCs as a viable treatment strategy in advanced solid tumors. Several target-specific ADCs have shown promise in treatment-refractory NSCLC, including agents targeting HER2, HER3, TROP2, CEACAM5, and MET, among others, with multiple confirmatory phase 3 trials ongoing. Critically, ADCs have demonstrated efficacy signals in both driver mutation-positive and mutation-negative advanced NSCLC, reinforcing their potential as an efficacious treatment strategy that transcends diverse tumor biology in advanced NSCLC. ADCs are a promising class of anti-cancer therapeutics that have significant potential in advanced NSCLC. Beyond confirmatory phase 3 trials, several questions remain including optimal agent sequencing, combinatorial methods, and unique toxicity management.
Authors: M N Saleh; S Sugarman; J Murray; J B Ostroff; D Healey; D Jones; C R Daniel; D LeBherz; H Brewer; N Onetto; A F LoBuglio Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: Feng Tian; Yingchun Lu; Anthony Manibusan; Aaron Sellers; Hon Tran; Ying Sun; Trung Phuong; Richard Barnett; Brad Hehli; Frank Song; Michael J DeGuzman; Semsi Ensari; Jason K Pinkstaff; Lorraine M Sullivan; Sandra L Biroc; Ho Cho; Peter G Schultz; John DiJoseph; Maureen Dougher; Dangshe Ma; Russell Dushin; Mauricio Leal; Lioudmila Tchistiakova; Eric Feyfant; Hans-Peter Gerber; Puja Sapra Journal: Proc Natl Acad Sci U S A Date: 2014-01-17 Impact factor: 11.205
Authors: A W Tolcher; S Sugarman; K A Gelmon; R Cohen; M Saleh; C Isaacs; L Young; D Healey; N Onetto; W Slichenmyer Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: Nadia Howlader; Gonçalo Forjaz; Meghan J Mooradian; Rafael Meza; Chung Yin Kong; Kathleen A Cronin; Angela B Mariotto; Douglas R Lowy; Eric J Feuer Journal: N Engl J Med Date: 2020-08-13 Impact factor: 91.245